雲南鍺業(002428.SZ):目前公司化合物半導體材料已向國內外多家客户供貨
格隆匯8月13日丨雲南鍺業(002428.SZ)在投資者互動平台表示,目前公司化合物半導體材料已向國內外多家客户供貨,經反饋使用情況良好,公司正在積極開展市場開拓工作,爭取更多訂單。目前世界範圍內,化合物半導體材料(襯底)主要集中於美、日等發達國家。在全球範圍內以日本住友電氣工業株式會社、JX日礦日石金屬株式會社、美國AXT、德國費裏伯格化合物材料公司等國際知名企業從事化合物半導體材料生產、銷售。上述企業均擁有較強的研發能力、技術儲備、銷售渠道和市場聲譽。近年來,國內化合物半導體材料行業發展速度明顯加快,國產化趨勢明顯加快。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.